JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sadeque, A. J.M.
Right arrow Articles by Rettie, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sadeque, A. J.M.
Right arrow Articles by Rettie, A. E.

Vol. 283, Issue 2, 698-703, 1997

Human CYP2C9 and CYP2A6 Mediate Formation of the Hepatotoxin 4-Ene-Valproic Acid1

Abu J.M. Sadeque, Michael B. Fisher, Kenneth R. Korzekwa2 , Frank J. Gonzalez and Allan E. Rettie

Department of Medicinal Chemistry, University of Washington, Seattle, Washington (A.J.M.S., M.B.F., A.E.R) and Laboratory of Molecular Carcinogenesis, National Cancer Institute, Bethesda, Maryland (K.R.K., F.J.G.)

Cytochrome P450-dependent desaturation of the anticonvulsant drug valproic acid (VPA) results in formation of the hepatotoxin, 4-ene-VPA. Polytherapy with other anticonvulsants which are known P450 inducers increases the flux through this bioactivation pathway. The aim of the present study was to identify specific, inducible forms of human liver P450 which catalyze terminal desaturation of VPA. Oxidized VPA metabolites formed in an NADPH-dependent manner by human liver microsomes were quantified by gas-chromatography/mass spectrometry. In vitro reaction conditions were established which reflected the product profile found in vivo. Production of 4-ene-VPA by microsomal P450s could be inhibited significantly by coumarin, sulfaphenazole and diethyldithiocarbamate, but not by triacetyloleandomycin, quinidine or furafylline. Recombinant human CYP3A4 did not form detectable levels of 4-ene-VPA and, of nine additional isoforms expressed in either HepG2 or lymphoblastoid cells which were screened for VPA desaturase activity, only CYP2C9 and CYP2A6 formed detectable levels of metabolite. Consequently, CYP3A4, the isoform usually associated with induction by anticonvulsants cannot be responsible for the enhanced 4-ene-VPA formation that occurs during polytherapy. Instead, enhanced activity in vivo likely results from induction of CYP2A6 and/or CYP2C9.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Toxicol SciHome page
T. K. L. Kiang, P. C. Ho, M. R. Anari, V. Tong, F. S. Abbott, and T. K. H. Chang
Contribution of CYP2C9, CYP2A6, and CYP2B6 to Valproic Acid Metabolism in Hepatic Microsomes from Individuals with the CYP2C9*1/*1 Genotype
Toxicol. Sci., December 1, 2006; 94(2): 261 - 271.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
N. B. Sandson, C. Marcucci, D. L. Bourke, and R. Smith-Lamacchia
An Interaction Between Aspirin and Valproate: The Relevance of Plasma Protein Displacement Drug-Drug Interactions
Am J Psychiatry, November 1, 2006; 163(11): 1891 - 1896.
[Full Text] [PDF]

Home page
 PsychosomaticsHome page
N. B. Sandson, S. C. Armstrong, and K. L. Cozza
An Overview of Psychotropic Drug-Drug Interactions
Psychosomatics, October 1, 2005; 46(5): 464 - 494.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. Sobol, B. Yagen, I. Winkler, M. Britzi, D. Gibson, and M. Bialer
PHARMACOKINETICS AND METABOLISM OF A NEW POTENT ANTIEPILEPTIC DRUG, 2,2,3,3-TETRAMETHYCYCLOPROPANECARBONYLUREA, IN RATS
Drug Metab. Dispos., October 1, 2005; 33(10): 1538 - 1546.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Fujieda, H. Yamazaki, T. Saito, K. Kiyotani, M. A. Gyamfi, M. Sakurai, H. Dosaka-Akita, Y. Sawamura, J. Yokota, H. Kunitoh, et al.
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers
Carcinogenesis, December 1, 2004; 25(12): 2451 - 2458.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. Ginsberg, D. Hattis, R. Miller, and B. Sonawane
Pediatric Pharmacokinetic Data: Implications for Environmental Risk Assessment for Children
Pediatrics, April 1, 2004; 113(4/S1): 973 - 983.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S P. Sattar, S. Ramaswamy, S. C Bhatia, and F. Petty
Somnambulism Due to Probable Interaction of Valproic Acid and Zolpidem
Ann. Pharmacother., October 1, 2003; 37(10): 1429 - 1433.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. D. Kharasch, D. C. Hankins, and J. K. Taraday
Single-Dose Methoxsalen Effects on Human Cytochrome P-450 2A6 Activity
Drug Metab. Dispos., January 1, 2000; 28(1): 28 - 33.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
C. Wandel, R. H. Böcker, H. Böhrer, J. X. deVries, W. Hofmann, K. Walter, B. Kleingeist, S. Neff, R. Ding, I. Walter-Sack, et al.
Relationship between Hepatic Cytochrome P450 3A Content and Activity and the Disposition of Midazolam Administered Orally
Drug Metab. Dispos., February 1, 1998; 26(2): 110 - 114.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.